Clinical data | |
---|---|
Trade names | Vasotec, Renitec, Enacard, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a686022 |
Pregnancy category |
|
Routes of administration |
by mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 60% (by mouth) |
Metabolism | liver (to enalaprilat) |
Biological half-life | 11 hours (enalaprilat) |
Excretion | kidney |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.119.661 |
Chemical and physical data | |
Formula | C20H28N2O5 |
Molar mass | 376.447 g/mol |
3D model (Jmol) | |
Melting point | 143 to 144.5 °C (289.4 to 292.1 °F) |
|
|
|
|
Enalapril, sold under the brand name Vasotec among others, is a medication used to treat high blood pressure, diabetic kidney disease, and heart failure. For heart failure it is generally used with a diuretic such as furosemide. It is given by mouth or injection into a vein. Onset of effects are typically within an hour when taken by mouth and last for up to day.
Common side effects include headache, tiredness, lightheadedness with standing, and cough. Serious side effects include angioedema and low blood pressure. Use during pregnancy is believed to result in harm to the baby. Enalapril is in the angiotensin-converting-enzyme inhibitor (ACEi) family of medications.
Enalapril was patented in 1978 and came into medical use in 1984. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 0.08 to 0.80 USD per month. In the United States it costs about 25 to 50 USD per month.
Enalapril is used to treat hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction. It has been proven to protect the function of the kidneys in hypertension, heart failure, and diabetes, and may be used in the absence of hypertension for its kidney protective effects. It is widely used in chronic kidney failure. Furthermore, enalapril is an emerging treatment for psychogenic polydipsia. A double-blind, placebo-controlled trial showed that when used for this purpose, enalapril lead to decreased water consumption (determined by urine output and osmality) in 60% of patients.